Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2025
Resources
All Resources
2024 Savings Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Press Releases
Press Release
Share
Press Release
Oct 16, 2024
| AAM
$2 Generics List Not the Solution
Press Release
Sep 25, 2024
| AAM
John Murphy Named President and CEO of AAM
Press Release
Sep 24, 2024
| Comms Temp
AAM Urges Congress to Pass Key Bills Considered by the Senate HELP Committee This Week
Press Release
Sep 24, 2024
| AAM
40 Years of Hatch-Waxman – Trillions in Savings for Patients
Press Release
Sep 18, 2024
| AAM
Generic Medicines Increase Patient Access More Than Government Negotiated Price Controls
Press Release
Sep 13, 2024
| AAM
Statement Regarding Senate Judiciary Committee Markup of the PREVAIL Act and the PERA Act
Press Release
Sep 10, 2024
| AAM
AAM and the Biosimilar Council Host Patent Abuse Congressional Briefing: What’s Truly Preventing Low-Cost Medicines from Getting to Patients: A Look at the Broken Patent System
Press Release
Sep 5, 2024
| AAM
Generic and Biosimilar Medicines Save $445 Billion in 2023
Press Release
Aug 15, 2024
| Ashley Henyan
Benefit Projected by CMS Price Setting Cannot Compare to Benefit of Generic and Biosimilar Medicines
Press Release
Jul 9, 2024
| Brian Hart
FTC Report Critical of PBMs Highlights Middlemen Profits Over Patient Savings
Press Release
Jun 26, 2024
| Ashley Henyan
Blog: Bill Addressing Drug Shortages Provides Long Overdue Relief from Penalties Hurting Generic Drug Market
Press Release
May 30, 2024
| Brian Hart
AAM Submits Comments to HHS and FTC on the Impact of GPOs and Wholesalers on Access to Generic Medicines
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2025
Resources
All Resources
2024 Savings Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action